Cargando…
Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis
Peginesatide is the newest erythropoietin-stimulating agent (ESA) in the quest for the ideal treatment of anemia in chronic kidney disease (CKD) patients. Reduced frequency of administration along with a possibly lower cost as a result of simpler manufacturing techniques compared with other availabl...
Autores principales: | Kaushik, Tarun, Yaqoob, Muhammad Magdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848525/ https://www.ncbi.nlm.nih.gov/pubmed/24348017 http://dx.doi.org/10.2147/BTT.S34935 |
Ejemplares similares
-
Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis
por: Mikhail, Ashraf
Publicado: (2012) -
Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
por: Valliant, Amanda, et al.
Publicado: (2013) -
A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis
por: Naik, Himanshu, et al.
Publicado: (2013) -
An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients
por: Besarab, Anatole, et al.
Publicado: (2012) -
Effects of Peginesatide Injection on QTc Interval in Healthy Adults
por: Czerniak, Richard, et al.
Publicado: (2014)